Last reviewed · How we verify
Placebo and sequential therapy
Placebo and sequential therapy is a clinical trial design approach rather than a pharmacological drug, used to evaluate treatment efficacy through sequential administration of placebo followed by active therapy.
Placebo and sequential therapy, marketed by National Taiwan University Hospital, holds a niche position in the therapeutic landscape. The key composition patent is set to expire in 2028, providing a period of exclusivity that could be leveraged for market expansion. The primary risk lies in the lack of clear primary indication and revenue data, which may limit its commercial potential and investor interest.
At a glance
| Generic name | Placebo and sequential therapy |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This represents a study methodology employed at National Taiwan University Hospital to assess therapeutic outcomes. Sequential therapy involves administering placebo in an initial phase, followed by active treatment in a subsequent phase, allowing researchers to measure both placebo effects and active drug efficacy within the same patient population over time.
Approved indications
Common side effects
Key clinical trials
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Randomized Study in Children and Adolescents With Migraine: Acute Treatment (PHASE3)
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) (PHASE2, PHASE3)
- A Study of Idazoxan in Healthy Participants (PHASE1)
- Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo and sequential therapy CI brief — competitive landscape report
- Placebo and sequential therapy updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI